Consolidative Prostate Radiotherapy in Metastatic Prostate Cancer

This study tests whether adding targeted radiation therapy to the prostate (the original tumor site) improves survival and helps control disease in men who have already been diagnosed with metastatic prostate cancer (cancer that has spread to other parts of the body) and are receiving systemic (whole-body) hormone therapy. **You may be eligible if...** - You are 18 or older - You have confirmed metastatic prostate cancer (spread to bones or other sites) - You are already receiving or planning to receive hormone therapy (ADT), with or without additional targeted drugs (ARATsuch as enzalutamide or abiraterone) - You are also planned to receive external beam radiation therapy to the pelvis - Your general health is good (ECOG 0 or 1) **You may NOT be eligible if...** - You have previously received radiation therapy to the pelvis - You have active inflammatory bowel disease such as ulcerative colitis or Crohn's disease - You have conditions that make radiation therapy unsafe or not recommended Talk to your doctor to see if this trial is right for you.